The Role of SIRT1 in Leukemia.

IF 3.8 2区医学 Q2 ONCOLOGY

Current Treatment Options in Oncology Pub Date : 2024-10-01 Epub Date: 2024-10-02 DOI:10.1007/s11864-024-01265-6

Zhongqi Wu, Tianxin Lyu, Leizhen Wu, Hui Yang, Wenqiang Li

{"title":"The Role of SIRT1 in Leukemia.","authors":"Zhongqi Wu, Tianxin Lyu, Leizhen Wu, Hui Yang, Wenqiang Li","doi":"10.1007/s11864-024-01265-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Opinion statement: </strong>Leukemia is a type of hematological malignancy (HM) caused by uncontrolled proliferation, apoptosis, and differentiation of hematopoietic stem cells (HSCs). Leukemia cells proliferate greatly in the bone marrow (BM), infiltrate other tissues and organs, and affect the normal hematopoietic function. Although the emergence of new targeted agents and immune agents has improved the prognosis of patients, due to the complex pathogenic factors and heterogeneity of leukemia, there are still some patients with poor prognosis. Recent studies have shown that silent information regulator 1 (SIRT1) is involved in the proliferation, apoptosis, metabolism, and senescence of leukemia cells. As a double-edged sword in leukemia cells, SIRT1 can both promote and inhibit the growth of leukemia cells. Since its mechanism of action has not been elucidated, it is urgent to explore the regulatory mechanism of SIRT1 in leukemia. In this review, we discussed the mechanisms of SIRT1 in different aspects of leukemia, providing a theoretical basis for the treatment of patients with leukemia.</p>","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"1283-1288"},"PeriodicalIF":3.8000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Treatment Options in Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11864-024-01265-6","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/2 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Opinion statement: Leukemia is a type of hematological malignancy (HM) caused by uncontrolled proliferation, apoptosis, and differentiation of hematopoietic stem cells (HSCs). Leukemia cells proliferate greatly in the bone marrow (BM), infiltrate other tissues and organs, and affect the normal hematopoietic function. Although the emergence of new targeted agents and immune agents has improved the prognosis of patients, due to the complex pathogenic factors and heterogeneity of leukemia, there are still some patients with poor prognosis. Recent studies have shown that silent information regulator 1 (SIRT1) is involved in the proliferation, apoptosis, metabolism, and senescence of leukemia cells. As a double-edged sword in leukemia cells, SIRT1 can both promote and inhibit the growth of leukemia cells. Since its mechanism of action has not been elucidated, it is urgent to explore the regulatory mechanism of SIRT1 in leukemia. In this review, we discussed the mechanisms of SIRT1 in different aspects of leukemia, providing a theoretical basis for the treatment of patients with leukemia.

查看原文本刊更多论文

SIRT1 在白血病中的作用

意见陈述：白血病是造血干细胞（HSCs）增殖、凋亡和分化失控引起的一种血液恶性肿瘤（HM）。白血病细胞在骨髓（BM）中大量增殖，浸润其他组织和器官，影响正常造血功能。虽然新的靶向药物和免疫制剂的出现改善了患者的预后，但由于白血病的致病因素复杂、异质性强，仍有部分患者预后较差。最近的研究表明，沉默信息调节因子1（SIRT1）参与了白血病细胞的增殖、凋亡、代谢和衰老。作为白血病细胞的双刃剑，SIRT1 既能促进白血病细胞的生长，也能抑制其生长。由于其作用机制尚未阐明，因此探索SIRT1在白血病中的调控机制迫在眉睫。在这篇综述中，我们探讨了 SIRT1 在白血病不同方面的作用机制，为白血病患者的治疗提供了理论依据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Treatment Options in Oncology ONCOLOGY-

CiteScore

7.10

自引率

0.00%

发文量

113

审稿时长

>12 weeks

期刊介绍： This journal aims to review the most important, recently published treatment option advances in the field of oncology. By providing clear, insightful, balanced contributions by international experts, the journal intends to facilitate worldwide approaches to cancer treatment. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as endocrine tumors, lymphomas, neuro-oncology, and cancers of the breast, head and neck, lung, skin, gastrointestinal tract, and genitourinary region. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. We also provide commentaries from well-known oncologists, and an international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research.